Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon
File Type:
PDFItem Type:
Journal ArticleDate:
2023Access:
openAccessCitation:
Ryan, T.A.J. and Hooftman, A. and Rehill, A.M. and Johansen, M.D. and Brien, E.C.O. and Toller-Kawahisa, J.E. and Wilk, M.M. and Day, E.A. and Weiss, H.J. and Sarvari, P. and Vozza, E.G. and Schramm, F. and Peace, C.G. and Zotta, A. and Miemczyk, S. and Nalkurthi, C. and Hansbro, N.G. and McManus, G. and O’Doherty, L. and Gargan, S. and Long, A. and Dunne, J. and Cheallaigh, C.N. and Conlon, N. and Carty, M. and Fallon, P.G. and Mills, K.H.G. and Creagh, E.M. and Donnell, J.S.O. and Hertzog, P.J. and Hansbro, P.M. and McLoughlin, R.M. and Wygrecka, M. and Preston, R.J.S. and Zasłona, Z. and Neill, L.A.J.O., Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon, Nature Communications, 14, 1, 2023Download Item:
Abstract:
Excessive inflammation-associated coagulation is a feature of infectious diseases, occurring in such conditions as bacterial sepsis and COVID-19. It can lead to disseminated intravascular coagulation, one of the leading causes of mortality worldwide. Recently, type I interferon (IFN) signaling has been shown to be required for tissue factor (TF; gene name F3) release from macrophages, a critical initiator of coagulation, providing an important mechanistic link between innate immunity and coagulation. The mechanism of release involves type I IFN-induced caspase-11 which promotes macrophage pyroptosis. Here we find that F3 is a type I IFN-stimulated gene. Furthermore, F3 induction by lipopolysaccharide (LPS) is inhibited by the anti-inflammatory agents dimethyl fumarate (DMF) and 4-octyl itaconate (4-OI). Mechanistically, inhibition of F3 by DMF and 4-OI involves suppression of Ifnb1 expression. Additionally, they block type I IFN- and caspase-11-mediated macrophage pyroptosis, and subsequent TF release. Thereby, DMF and 4-OI inhibit TF-dependent thrombin generation. In vivo, DMF and 4-OI suppress TF-dependent thrombin generation, pulmonary thromboinflammation, and lethality induced by LPS, E. coli, and S. aureus, with 4-OI additionally attenuating inflammation-associated coagulation in a model of SARS-CoV-2 infection. Our results identify the clinically approved drug DMF and the pre-clinical tool compound 4-OI as anticoagulants that inhibit TF-mediated coagulopathy via inhibition of the macrophage type I IFN-TF axis.
Author's Homepage:
http://people.tcd.ie/millskhttp://people.tcd.ie/cartymi
http://people.tcd.ie/nicheac2
http://people.tcd.ie/mclougrm
Description:
PUBLISHEDcited By 0
Type of material:
Journal ArticleCollections
Series/Report no:
Nature Communications14
1
Availability:
Full text availableDOI:
http://dx.doi.org/10.1038/s41467-023-39174-1Metadata
Show full item recordLicences: